Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZBTB20 antisense RNA 5 (ZBTB20-AS5) is classified as a long non-coding RNA (lncRNA) and represents a putative transcript produced from the antisense strand overlapping the ZBTB20 gene. No peer-reviewed functional studies, disease associations, or documentation as a therapeutic or diagnostic target are available for ZBTB20-AS5 as of current knowledge. The underlying sense gene, **ZBTB20 (Zinc finger and BTB domain-containing protein 20)**, encodes a transcriptional repressor involved in cellular development, differentiation, metabolism, and immune regulation, and is implicated in cancer and other diseases[1][2][3]. However, there is *no published evidence or curated database entry defining ZBTB20-AS5 itself as a protein, receptor, or established therapeutic target* or that it possesses known biological activity distinct from generic lncRNA annotation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZBTB20 antisense RNA 5 (ZBTB20-AS5).